Chai Discovery's $400M Series C at $3.8B: Index, Kleiner, Sequoia Bet on AI Molecules
Index Ventures led Chai Discovery's $400M Series C at $3.8B as Eli Lilly, Novartis, and Pfizer put AI-designed molecules into real discovery pipelines.
Explore our latest articles on artificial-intelligence — covering venture capital deals, fund activity, startup fundraising strategy, and investor research relevant to this topic.
Whether you're a founder building an investor target list, an analyst tracking deal flow, or an operator researching market trends, the articles below provide practical, up-to-date venture capital intelligence.
Browse all artificial-intelligence articles below, or use our investor list to research active investors by stage and sector.
Index Ventures led Chai Discovery's $400M Series C at $3.8B as Eli Lilly, Novartis, and Pfizer put AI-designed molecules into real discovery pipelines.
Radical Ventures led Prime Intellect’s $130M Series A at a $1B valuation — compute, RL, evals, and deployment so enterprises can train their own agents without renting a frontier lab.
Lightspeed Venture Partners backed Proxima Fusion’s Series A and stayed active across AI-native deals like Patronus AI and Eagle in mid-2026.
Bain Capital Ventures co-led Reserv’s $20M Series A with Altai Ventures to expand generative-AI insurance claims analysis tools.
B Capital Group closed its Ascent Fund III at a $500M hard cap, nearly doubling its predecessor to back seed–Series B AI, healthcare, and frontier-tech startups.
Straiker raised $64M Series A (total $85M) with Marathon leading and Bain Capital Ventures returning — discovery, adversarial testing, and runtime defense for enterprise AI agents.